IndieBio

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BiomeSense develops an integrated hardware, software, and data platform to scale microbiome data collection and analysis for clinical research. The company integrates at-home monitoring of the gut microbiome through its GutLab smart-bathroom system with the MetaBiome time-series analytics platform to connect microbiome changes with clinical outcomes in real time. Its platform supports large-scale, densely longitudinal datasets to discover, validate, and commercialize microbiome biomarkers, enabling clinicians to apply microbiome insights to improve human health. Founded in 2018 and based in Chicago, BiomeSense seeks to advance precision medicine by providing end-to-end microbiome measurement and analytics.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Dalton Bioanalytics develops analytical technology that digitizes the biochemical composition of blood and translates its digital signature into actionable health insights. The platform enables monitoring of plasma analytes (proteins, lipids, electrolytes, and small molecules) through a single assay, supporting multi-omic biology to facilitate discovery, development, and delivery of precision medicine. By digitizing blood signals, the company addresses inefficiency and cost associated with traditional laboratory testing and aims to unlock comprehensive narratives about internal biology for research and clinical use.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

BiomeSense develops an integrated hardware, software, and data platform to scale microbiome data collection and analysis for clinical research. The company integrates at-home monitoring of the gut microbiome through its GutLab smart-bathroom system with the MetaBiome time-series analytics platform to connect microbiome changes with clinical outcomes in real time. Its platform supports large-scale, densely longitudinal datasets to discover, validate, and commercialize microbiome biomarkers, enabling clinicians to apply microbiome insights to improve human health. Founded in 2018 and based in Chicago, BiomeSense seeks to advance precision medicine by providing end-to-end microbiome measurement and analytics.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Dalton Bioanalytics develops analytical technology that digitizes the biochemical composition of blood and translates its digital signature into actionable health insights. The platform enables monitoring of plasma analytes (proteins, lipids, electrolytes, and small molecules) through a single assay, supporting multi-omic biology to facilitate discovery, development, and delivery of precision medicine. By digitizing blood signals, the company addresses inefficiency and cost associated with traditional laboratory testing and aims to unlock comprehensive narratives about internal biology for research and clinical use.

Ivy Natal is a biotechnology company focused on addressing infertility through innovative reproductive solutions. The company has developed a skin biopsy technology that enables the creation of human egg cells from skin samples. This process activates the existing DNA within skin cells to transform them into healthy egg cells, offering a novel alternative to traditional in vitro methods for producing eggs and sperm. By circumventing the challenges associated with conventional reproductive techniques, Ivy Natal aims to provide couples, including those in same-sex relationships, with the opportunity to have genetically related children.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Dalton Bioanalytics develops analytical technology that digitizes the biochemical composition of blood and translates its digital signature into actionable health insights. The platform enables monitoring of plasma analytes (proteins, lipids, electrolytes, and small molecules) through a single assay, supporting multi-omic biology to facilitate discovery, development, and delivery of precision medicine. By digitizing blood signals, the company addresses inefficiency and cost associated with traditional laboratory testing and aims to unlock comprehensive narratives about internal biology for research and clinical use.

Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Antibiotic Adjuvant, Inc. is a healthcare technology company based in Gainesville, Florida, founded in 2014. The company specializes in developing decision support software aimed at reducing infections and antibiotic resistance in healthcare settings. Its flagship product, SmartSteward, provides a comprehensive platform designed to optimize antibiotic use in real-time. The software caters to healthcare administrators by offering tools and educational resources, supports physicians with relevant prescribing information, and assists nurses through surveillance tools and infection reporting mechanisms. Antibiotic Adjuvant's innovative approach seeks to improve the management of antibiotic prescriptions, addressing the complexities of usage patterns and enhancing resistance control in clinical environments.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.

BiomeSense develops an integrated hardware, software, and data platform to scale microbiome data collection and analysis for clinical research. The company integrates at-home monitoring of the gut microbiome through its GutLab smart-bathroom system with the MetaBiome time-series analytics platform to connect microbiome changes with clinical outcomes in real time. Its platform supports large-scale, densely longitudinal datasets to discover, validate, and commercialize microbiome biomarkers, enabling clinicians to apply microbiome insights to improve human health. Founded in 2018 and based in Chicago, BiomeSense seeks to advance precision medicine by providing end-to-end microbiome measurement and analytics.

NeuroQore, Inc. is a Canadian company based in Ottawa, founded in 2012, that specializes in developing innovative neuromodulation treatment systems aimed at addressing treatment-resistant depression and related neurobehavioral conditions. The company's flagship product is a monophasic repetitive transcranial magnetic stimulation system that utilizes a unique semiconductor switch to emit a novel magnetic pulse. This technology is designed to help patients overcome challenges associated with major depressive disorder and suicidality, ultimately improving their quality of life. NeuroQore collaborates with leading universities and research clinics globally, reflecting its commitment to advancing the field of neuromodulation and transforming the lives of those affected by these debilitating disorders.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Osiris Bio

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Antibiotic Adjuvant, Inc. is a healthcare technology company based in Gainesville, Florida, founded in 2014. The company specializes in developing decision support software aimed at reducing infections and antibiotic resistance in healthcare settings. Its flagship product, SmartSteward, provides a comprehensive platform designed to optimize antibiotic use in real-time. The software caters to healthcare administrators by offering tools and educational resources, supports physicians with relevant prescribing information, and assists nurses through surveillance tools and infection reporting mechanisms. Antibiotic Adjuvant's innovative approach seeks to improve the management of antibiotic prescriptions, addressing the complexities of usage patterns and enhancing resistance control in clinical environments.

Nivien Therapeutics is a biomedical company focused on developing medicines that enhance chemotherapy and immunotherapy for treatment-resistant cancers. Founded in 2016 and based in Boston, Massachusetts, the company has developed first small-molecule inhibitors targeting the Hippo signaling pathway, a mechanism implicated in cancer resistance. Its program aims to de-risk transfers of technology assets from leading research institutes and to build a platform that advances IO-chemo combination therapies, with an emphasis on expanding options for patients who do not respond to standard treatments.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Onconetics Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies aimed at treating cancer and other genetic disorders. Established in 2016 and located in Mill Valley, California, Onconetics utilizes a unique therapeutic platform that incorporates a genetic switch to activate apoptotic inducers, selectively targeting tumor cells while preserving healthy tissue. The company is dedicated to advancing personalized medicine by integrating established gene therapy techniques with innovative research, striving to create effective treatments that reduce the invasiveness and side effects associated with traditional cancer therapies. Through its efforts, Onconetics aims to enhance patient outcomes and improve the overall quality of life for individuals affected by cancer and genetic conditions.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative therapies for incurable cancers and neurodegenerative diseases. The company utilizes a machine vision and learning platform to drive diseased stem cells to non-diseased states by identifying drugs that induce epigenetic changes. Its proprietary Microscopic Imaging of Epigenetic Landscapes (MIEL) technology facilitates the discovery of small molecules capable of differentiating or reversing cancerous cells into benign types, potentially offering curative outcomes. Founded in 2017 and headquartered in San Diego, California, Stelvio Therapeutics combines scientific creativity, clinical excellence, and professional management to advance novel drug therapies and precision medicine diagnostics, with a particular emphasis on personalized treatments for conditions such as glioblastoma.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.

NeuroQore, Inc. is a Canadian company based in Ottawa, founded in 2012, that specializes in developing innovative neuromodulation treatment systems aimed at addressing treatment-resistant depression and related neurobehavioral conditions. The company's flagship product is a monophasic repetitive transcranial magnetic stimulation system that utilizes a unique semiconductor switch to emit a novel magnetic pulse. This technology is designed to help patients overcome challenges associated with major depressive disorder and suicidality, ultimately improving their quality of life. NeuroQore collaborates with leading universities and research clinics globally, reflecting its commitment to advancing the field of neuromodulation and transforming the lives of those affected by these debilitating disorders.

Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.

NeuroQore, Inc. is a Canadian company based in Ottawa, founded in 2012, that specializes in developing innovative neuromodulation treatment systems aimed at addressing treatment-resistant depression and related neurobehavioral conditions. The company's flagship product is a monophasic repetitive transcranial magnetic stimulation system that utilizes a unique semiconductor switch to emit a novel magnetic pulse. This technology is designed to help patients overcome challenges associated with major depressive disorder and suicidality, ultimately improving their quality of life. NeuroQore collaborates with leading universities and research clinics globally, reflecting its commitment to advancing the field of neuromodulation and transforming the lives of those affected by these debilitating disorders.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Founded in 2015, Truust Neuroimaging specializes in enhancing neuro-imaging systems' resolution at a fraction of the cost of equivalent hardware. This advancement enables breakthroughs in brain research, clinical diagnosis, and treatment of conditions like epilepsy, Alzheimer's, and Parkinson's.

MYi Diagnostics is a biomedical research company based in San Diego, California, founded in 2015 by Nicholas J. Schork, Devon Cayer, and Kristopher L. Nazor. The company specializes in multiplexed proteomic profiling for precision medicine, focusing on developing single-cell quantification technology to identify unique biomarkers in patient biopsies. This technology aims to replace numerous targeted diagnostics for various conditions, including individual cancers, infectious diseases, metabolic conditions, and other disorders. By generating actionable individualized information, MYi Diagnostics helps streamline clinical intervention strategies, providing healthcare providers with valuable insights for personalized treatment plans.